News from AHA 2024: ATTRibute-CM-OLE; acoramidis; TTR

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

No benefit of routine spironolactone post-MI
No benefit of routine spironolactone post-MI
Heart Matters
No benefit of routine spironolactone post-MI
- Sanjit Jolly, MD
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
Heart Matters
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Heart Matters
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Audit and feedback strategy for pharmacists improves HF care
Audit and feedback strategy for pharmacists improves HF care
Heart Matters
Audit and feedback strategy for pharmacists improves HF care
- Alexander Sandhu, MD

Acoramidis reduces all-cause mortality in ATTR-CM